PRODUCTS IN ORAL APPLICATIONS
Oral Applications
In oral applications phospholipids aim to enhance oral uptake and bioavailability of poorly water-soluble drug substances. They can reduce irritation of the stomach or help to protect the API from degradation.
The phospholipids are mainly applied in emulsions, dispersions, mixed micelles, (pro) liposomes, solid dispersions, and non-aqueous phospholipid formulations. They can serve as wetting agents, emulsifiers, solubilizers, or lipid matrix forming excipients. Such formulations can be converted into dry forms such as granules, powders, and tablets by adding appropriate excipients or directly filled, e.g., into capsules, sachets, or bottles.
Liquid Phospholipid Formulations
Liquid, non-aqueous concentrates of phospholipids in combination with oils or a water-miscible solvent like propylene glycol are suitable for dissolving APIs. Diluted in water, they help to disperse the API in the aqueous phase. They may be directly filled into capsules, bottles, or sachets as dosage form.
Emulsions
When the drug has sufficient solubility in oils, O/W emulsions or self-emulsifying systems can be prepared with phospholipids as emulsifiers or co-emulsifiers.
(Mixed) Micelles
(Mixed) Micelles comprising phospholipids and bile salts mimic natural gut solubilization systems and are valued solubilizers, even for pediatric use.
Solid Dispersions
A poorly soluble API and a phospholipid, for example, spray-dried with or without polymers, form solid dispersions with the amorphous state of the drug. Upon hydration, the phospholipids act as wetting agents and solubilizers.
Phospholipids as API’s
Polyunsaturated/Polyenyl Phospholipids (PPL) derived from soybean are used for the prevention and treatment of liver diseases. These phospholipids suppress the formation of detrimental Radical Oxygen Species (ROS). They are available either as soybean phospholipid raw material or as formulated liquid products.
The products shown below represent a selection of our extensive product range.
Products
Soybean | ||
LIPOID S 45 | Lecithin fraction with 45 % phosphatidylcholine | CAS-No. 8030-76-0 |
LIPOID S 75 | Phospholipids with 70 % phosphatidylcholine | CAS-No. 8030-76-0 |
LIPOID S 80 | PPL Phospholipids with 73 – 79 % phosphatidylcholine | CAS-No. 8030-76-0 |
SOLUTHIN® S 80 M | Phosphatidylcholine with magnesium chloride (powdered compound), phosphatidylcholine content ≥ 64.0 % | CAS-No. 8030-76-0 |
PHOSPHOLIPON® 90 G | Phosphatidylcholine, content ≥ 94.0 %, granulated | CAS-No. 97281-47-5 |
PHOSPHOLIPON® 80 H | Phospholipids, hydrogenated, with 70 % phosphatidylcholine | CAS-No. 92128-87-5 |
PHOSPHOLIPON® 90 H | Phosphatidylcholine, hydrogenated, content ≥ 90.0 % | CAS-No. 97281-48-6 |
LIPOID PPL-400 | Waxy formulations of PPL phospholipids in hard-fat and soybean oil, phosphatidylcholine content ≥ 53.0 % | CAS-No. 8030-76-0 |
LIPOID PPL-600 | Fluid formulation of PPL phospholipids in medium-chain triglycerides, phosphatidylcholine content ≥ 37.0 % | CAS-No. 8030-76-0 |
PHOSAL® MCT | 30 % LIPOID S 75 (USP-NF) in medium-chain trigylcerides (USP-NF) | |
PHOSAL® 50 PG | Phosphatidylcholine in propylene glycol, content ≥ 50.0 % | |
PHOSAL® 50 SA+ | Phospholipid formulation of phosphatidylcholine, content ≥ 50.0 % in safflower seed oil | |
PHOSAL® 53 MCT | Phosphatidylcholine in medium-chain triglyceride, content ≥ 53.0 % | |
PHOSAL® 75 SA | Phosphatidylcholine in ethanol and safflower oil, content ≥ 72.0 % | |
LIPOID GPC | sn-Glycero-3-phosphocholine, content ≥ 98.0 % | CAS-No. 28319-77-9 |
LIPOID GPC 50 Mix | Powder with 50 % sn-glycero-3-phosphocholine (GPC) from soybean | CAS-No. 28319-77-9 |
LIPOID GPC 85 F | Fluid concentrate of sn-Glycero-3-phosphocholine (≥ 98.0 %) in water | CAS-No. 28319-77-9 |
Non-GMO Soybean | ||
LIPOID P 45 | Lecithin fraction with 45 % phosphatidylcholine | CAS-No. 8030-76-0 |
LIPOID P 75 | Phospholipids with 70 % phosphatidylcholine | CAS-No. 8030-76-0 |
LIPOID P 100 | Phosphatidylcholine, content ≥ 90.0 % | CAS-No. 97281-47-5 |
LIPOID P LPC 80 | Lysophosphatidylcholine, content 80 % and ≤ 20 % phosphatidylcholine | CAS-No. 9008-30-4 |
LIPOID P 75-3 | Phospholipids, hydrogenated, with 70 % phosphatidylcholine | CAS-No. 92128-87-5 |
LIPOID P 100-3 | Phosphatidylcholine, hydrogenated, content ≥ 90.0 % | CAS-No. 97281-48-6 |
Sunflower (Non-GMO) | ||
LIPOID H 90 | Phosphatidylcholine, content ≥ 90.0 % | CAS-No. 97281-49-7 |
LIPOID H 100 | Phosphatidylcholine, content ≥ 94.0 % | CAS-No. 97281-49-7 |
LIPOID H 100-3 | Phosphatidylcholine from sunflower, hydrogenated, content ≥ 90.0 % | CAS-No. 92128-87-5 |
PHOSAL® H 50 | Phosphatidylcholine in sunflower oil, content ≥ 50.0 % | |
LIPOID H GPC | sn-Glycero-3-phosphocholine, content ≥ 98.0 % | CAS-No. 28319-77-9 |
- Pharmaceutical Applications
- Parenteral Applications [3]
- Oral Applications
- Topical Applications [4]
- Pulmonary Applications [5]
- Ocular Applications [6]
- Active Pharmaceutical Ingredients [7]